A tool to choose the best antibiotics for patients with drug-resistant tuberculosis
Official title: A clinical decision tool to optimize the selection of antibiotics for patients with rifampicin-resistant Tuberculosis
Funded at Yale University · NIH-10980109 · Data updated 2026-11-12
This study is working on a helpful tool for doctors to choose the best antibiotics for people with rifampicin-resistant tuberculosis, so they can get better treatment and avoid unnecessary side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | July 18, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $647,922 |
| NIH project number | 1R01AI177326-01A1 |
| Project ID | NIH-10980109 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with rifampicin-resistant tuberculosis who require antibiotic treatment.
✕Less likely to help
Patients who do not have drug-resistant tuberculosis or those who are not currently undergoing treatment may not benefit from this research.
What this research studies
This research aims to create a clinical decision tool that helps healthcare providers select the most effective antibiotics for patients suffering from rifampicin-resistant tuberculosis (RR-TB). By utilizing drug susceptibility tests, the tool will guide treatment decisions, reducing the reliance on standardized regimens that may not be optimal for every patient. The approach focuses on improving patient outcomes by minimizing treatment failures and side effects associated with ineffective antibiotic use. The research will involve collaboration with healthcare settings to ensure the tool is practical and accessible.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with drug-resistant tuberculosis, improving their chances of recovery.
How similar studies have gone: Other research has shown promise in developing decision-support tools for antibiotic selection, indicating that this approach could be effective.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Yaesoubi, Reza — Yale University
- Study coordinator: Yaesoubi, Reza
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.